Oncoquest-L vaccine
Phase 2Vaccine
Oncoquest-L vaccine is one of 41 biologic programs targeting Follicular Lymphoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
201 competitors in Follicular Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Fludara
SanofiPhase 3
Zydelig
GileadPhase 3
Rayos
RRoxane Laboratories
Phase 3
Kesimpta
NovartisPhase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Tazverik
EEpizyme, Inc.
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Copiktra
SSecuraBio
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oncoquest-L vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 2[1]
- Company
- XXEME Biopharma Inc.